Control of hepatitis B virus replication by interferons and toll-like receptor signaling pathways

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11618-11629

  Pei, Rong Juan ^a   Chen, Xin Wen ^a   Lu, Meng Ji ^a,b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Hepatitis B virus; Innate immune response; Interferon; Interferon stimulated genes; Toll like receptor

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CIRCULAR DNA; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; HISTONE; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; MYXOVIRUS RESISTANCE PROTEIN A; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; ANTIVIRUS AGENT;

CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; ENHANCER REGION; EPIGENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; LIFE CYCLE; MINICHROMOSOME; NONHUMAN; PROTEIN ACETYLATION; PROTEIN BINDING; PROTEIN METHYLATION; REVIEW; SIGNAL TRANSDUCTION; TETRATRICOPEPTIDE REPEAT; TRANSCRIPTION TERMINATION; VIROGENESIS; VIRUS CAPSID; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NUCLEOCAPSID; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MUTATION; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; MUTATION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84909606393     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11618     Document Type: Review

References (128)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68 [PMID: 10704474]
2. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8 [PMID: 16103976 DOI: 10.1055/s-2005-915644]
3. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24 Suppl 1: 17-21 [PMID: 15192797 DOI: 10.1055/s-2004-828674]
4. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004; 101: 6669-6674 [PMID: 15100412 DOI: 10.1073/pnas.0401771101]
5. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005; 79 : 9369-9380 [PMID: 16014900 DOI: 10.1128/JVI.79.15.9369-9380.2005]
6. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, Dusheiko GM, Jacobs M, Klenerman P, Maini MK. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137: 1289-1300 [PMID: 19591831 DOI: 10.1053/j.gastro.2009.06.054]
7. Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-3768 [PMID: 8170985]
8. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36 [PMID: 8574849]
9. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829 [PMID: 10221919]
10. Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011; 5 : 644-653 [PMID: 21484123 DOI: 10.1007/s12072-011-9261-3]
11. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282-284 [PMID: 20056291 DOI: 10.1016/j.jhep.2009.10.031]
12. Abou-Jaoudé G, Sureau C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J Virol 2007; 81: 13057-13066 [PMID: 17898062 DOI: 10.1128/JVI.01495-07]
13. Le Duff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009; 83: 12443-12451 [PMID: 19759159 DOI: 10.1128/JVI.01594-09]
14. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013; 57: 985-994 [PMID: 23161433 DOI: 10.1002/hep.26125]
15. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012; 1: e00049 [PMID: 23150796 DOI: 10.7554/eLife.00049]
16. Macovei A, Petrareanu C, Lazar C, Florian P, Branza-Nichita N. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J Virol 2013; 87: 6415-6427 [PMID: 23536683 DOI: 10.1128/JVI.00393-13]
17. Rabe B, Glebe D, Kann M. Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol 2006; 80: 5465-5473 [PMID: 16699026 DOI: 10.1128/JVI.02303-05]
18. Rabe B, Vlachou A, Panté N, Helenius A, Kann M. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 2003; 100: 9849-9854 [PMID: 12909718 DOI: 10.1073/pnas.1730940100]
19. Rabe B, Delaleau M, Bischof A, Foss M, Sominskaya I, Pumpens P, Cazenave C, Castroviejo M, Kann M. Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog 2009; 5: e1000563 [PMID: 19714236 DOI: 10.1371/journal.ppat.1000563]
20. Bock CT, Schranz P, Schröder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994; 8 : 215-229 [PMID: 7975268]
21. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49: S13-S21 [PMID: 19399811 DOI: 10.1002/hep.22881]
22. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229 [PMID: 15738952 DOI: 10.1038/nri1573]
23. Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011; 85: 11916-11927 [PMID: 21900164 DOI: 10.1128/JVI.05373-11]
24. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809, table of contents [PMID: 11585785 DOI: 10.1128/CMR.14.4.778-809.2001]
25. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 1999; 19: 817-828 [PMID: 10476925 DOI: 10.1089/107999099313325]
26. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43: 204-209 [PMID: 20187707 DOI: 10.3109/08916930903510880]
27. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012; 122: 529-537 [PMID: 22251702 DOI: 10.1172/JCI58847]
28. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897 [PMID: 15940624]
29. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013; 9: e1003613 [PMID: 24068929 DOI: 10.1371/journal.ppat.1003613]
30. Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C. Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol 2003; 77: 1885-1893 [PMID: 12525623]
31. Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, Tyrrell DL. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002; 76: 6356-6363 [PMID: 12021368]
32. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322 [PMID: 11119601 DOI: 10.1128/JVI.75.1.311-322.2001]
33. Civitico GM, Locarnini SA. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994; 203: 81-89 [PMID: 8030288 DOI: 10.1006/viro.1994.1457]
34. Su H, Yee JK. Regulation of hepatitis B virus gene expression by its two enhancers. Proc Natl Acad Sci USA 1992; 89: 2708-2712 [PMID: 1313564]
35. Tur-Kaspa R, Teicher L, Laub O, Itin A, Dagan D, Bloom BR, Shafritz DA. Alpha interferon suppresses hepatitis B virus enhancer activity and reduces viral gene transcription. J Virol 1990; 64: 1821-1824 [PMID: 2157063]
36. Nawa T, Ishida H, Tatsumi T, Li W, Shimizu S, Kodama T, Hikita H, Hosui A, Miyagi T, Kanto T, Hiramatsu N, Hayashi N, Takehara T. Interferon-α suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. Virology 2012; 432: 452-459 [PMID: 22832122 DOI: 10.1016/j.virol.2012.07.002]
37. Nakao K, Nakata K, Yamashita M, Tamada Y, Hamasaki K, Ishikawa H, Kato Y, Eguchi K, Ishii N. p48 (ISGF-3gamma) is involved in interferon-alpha-induced suppression of hepatitis B virus enhancer-1 activity. J Biol Chem 1999; 274: 28075-28078 [PMID: 10497156]
38. Rang A, Heise T, Will H. Lack of a role of the interferon-stimulated response element-like region in interferon alpha -induced suppression of Hepatitis B virus in vitro. J Biol Chem 2001; 276: 3531-3535 [PMID: 11106638 DOI: 10.1074/jbc.C000584200]
39. Alcantara FF, Tang H, McLachlan A. Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res 2002; 30: 2068-2075 [PMID: 11972347]
40. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA 1995; 92: 12398-12402 [PMID: 8618909]
41. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, Chisari FV. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996; 93: 4589-4594 [PMID: 8643448]
42. Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol 1999; 73: 474-481 [PMID: 9847353]
43. Heise T, Guidotti LG, Chisari FV. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol 1999; 73: 5767-5776 [PMID: 10364328]
44. Ehlers I, Horke S, Reumann K, Rang A, Grosse F, Will H, Heise T. Functional characterization of the interaction between human La and hepatitis B virus RNA. J Biol Chem 2004; 279 : 43437-43447 [PMID: 15302879 DOI: 10.1074/jbc.M402227200]
45. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264 [PMID: 10666256]
46. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173 [PMID: 10756029]
47. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76: 5646-5653 [PMID: 11991993]
48. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 2005; 102 : 9913-9917 [PMID: 15994231 DOI: 10.1073/pnas.0504273102]
49. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010; 84: 9332-9340 [PMID: 20610715 DOI: 10.1128/JVI.00918-10]
50. Zhang Q, Wang Y, Wei L, Jiang D, Wang JH, Rao HY, Zhu L, Chen H, Fei R, Cong X. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro. J Gastroenterol Hepatol 2008; 23 : 1747-1761 [PMID: 17559358 DOI: 10.1111/j.1440-1746.2007.04985.x]
51. Robek MD, Boyd BS, Wieland SF, Chisari FV. Signal transduction pathways that inhibit hepatitis B virus replication. Proc Natl Acad Sci USA 2004; 101: 1743-1747 [PMID: 14757813 DOI: 10.1073/pnas.0308340100]
52. Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, Chisari FV. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002; 76: 2617-2621 [PMID: 11861827]
53. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002; 76: 3570-3574 [PMID: 11884582]
54. Guidotti LG, McClary H, Loudis JM, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med 2000; 191: 1247-1252 [PMID: 10748242]
55. Wieland SF, Vega RG, Müller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV. Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes. J Virol 2003; 77: 1227-1236 [PMID: 12502840]
56. Vieira VC, Soares MA. The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int 2013; 2013 : 683095 [PMID: 23865062 DOI: 10.1155/2013/683095]
57. Zhang W, Zhang X, Tian C, Wang T, Sarkis PT, Fang Y, Zheng S, Yu XF, Xu R. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol 2008; 10 : 112-121 [PMID: 17672864 DOI: 10.1111/j.1462-5822.2007.01020.x]
58. Gonzalez MC, Suspène R, Henry M, Guétard D, Wain-Hobson S, Vartanian JP. Human APOBEC1 cytidine deaminase edits HBV DNA. Retrovirology 2009; 6: 96 [PMID: 19843348 DOI: 10.1186/1742-4690-6-96]
59. Rösler C, Köck J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsäcker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005; 42: 301-309 [PMID: 16025511 DOI: 10.1002/hep.20801]
60. Köck J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89: 1184-1191 [PMID: 18420796]
61. Jost S, Turelli P, Mangeat B, Protzer U, Trono D. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol 2007; 81: 10588-10596 [PMID: 17652382 DOI: 10.1128/JVI.02489-06]
62. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-1374 [PMID: 16729314 DOI: 10.1002/hep.21187]
63. Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Yatsuji H, Shirakawa K, Takaori-Kondo A, Chayama K. Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 2007; 88: 432-440 [PMID: 17251560 DOI: 10.1099/vir.0.82319-0]
64. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303: 1829 [PMID: 15031497 DOI: 10.1126/science.1092066]
65. Nguyen DH, Gummuluru S, Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007; 81 : 4465-4472 [PMID: 17314171 DOI: 10.1128/JVI.02510-06]
66. Nguyen DH, Hu J. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008; 82: 6852-6861 [PMID: 18480459 DOI: 10.1128/JVI.00465-08]
67. Baumert TF, Rösler C, Malim MH, von Weizsäcker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007; 46 : 682-689 [PMID: 17625792 DOI: 10.1002/hep.21733]
68. Rösler C, Köck J, Malim MH, Blum HE, von Weizsäcker F. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 2004; 305: 1403; author reply 1403 [PMID: 15353783 DOI: 10.1126/science.1100464]
69. Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 8321-8326 [PMID: 15919829 DOI: 10.1073/pnas.0408223102]
70. Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6: e1000928 [PMID: 20523896 DOI: 10.1371/journal.ppat.1000928]
71. Henry M, Guétard D, Suspène R, Rusniok C, Wain-Hobson S, Vartanian JP. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One 2009; 4: e4277 [PMID: 19169351 DOI: 10.1371/journal.pone.0004277]
72. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, Muramatsu M. Uracil DNA glycosylase counteracts APO-BEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog 2013; 9: e1003361 [PMID: 23696735 DOI: 10.1371/journal.ppat.1003361]
73. Proto S, Taylor JA, Chokshi S, Navaratnam N, Naoumov NV. APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication. Antiviral Res 2008; 78 : 260-267 [PMID: 18313151 DOI: 10.1016/j.antiviral.2008.01.006]
74. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, Trono D. APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol 2008; 82: 6585-6590 [PMID: 18434399 DOI: 10.1128/JVI.00216-08]
75. Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins in antiviral host defense. Biochimie 2007; 89: 812-818 [PMID: 17570575 DOI: 10.1016/j.biochi.2007.04.015]
76. Peltekian C, Gordien E, Garreau F, Meas-Yedid V, Soussan P, Willams V, Chaix ML, Olivo-Marin JC, Bréchot C, Kremsdorf D. Human MxA protein participates to the interferon-related inhibition of hepatitis B virus replication in female transgenic mice. J Hepatol 2005; 43: 965-972 [PMID: 16168514 DOI: 10.1016/j.jhep.2005.06.019]
77. Gordien E, Rosmorduc O, Peltekian C, Garreau F, Bréchot C, Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 2001; 75: 2684-2691 [PMID: 11222692 DOI: 10.1128/JVI.75.6.2684-2691.2001]
78. Li N, Zhang L, Chen L, Feng W, Xu Y, Chen F, Liu X, Chen Z, Liu W. MxA inhibits hepatitis B virus replication by interaction with hepatitis B core antigen. Hepatology 2012; 56: 803-811 [PMID: 22271421 DOI: 10.1002/hep.25608]
79. Fernández M, Quiroga JA, Martín J, Cotonat T, Pardo M, Horisberger MA, Carreño V. Impaired interferon induction of human MxA protein in chronic hepatitis B virus infection. J Med Virol 1997; 51: 332-337 [PMID: 9093949]
80. Rosmorduc O, Sirma H, Soussan P, Gordien E, Lebon P, Horisberger M, Bréchot C, Kremsdorf D. Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 1999; 80 (Pt 5): 1253-1262 [PMID: 10355772]
81. Fernández M, Quiroga JA, Carreño V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J Gen Virol 2003; 84: 2073-2082 [PMID: 12867637]
82. Xiong W, Wang X, Liu X, Xiang L, Zheng L, Yuan Z. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication. Virology 2004; 319: 306-314 [PMID: 14980490 DOI: 10.1016/j.virol.2003.11.005]
83. Li J, Lin S, Chen Q, Peng L, Zhai J, Liu Y, Yuan Z. Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 2010; 84: 6387-6399 [PMID: 20410269 DOI: 10.1128/JVI.00236-10]
84. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 2007; 88: 3260-3269 [PMID: 18024894 DOI: 10.1099/ vir.0.82959-0]
85. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774 [PMID: 15459668 DOI: 10.1038/nri1457]
86. Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, Saito K, Takemura M, Imawari M, Moriwaki H, Seishima M. Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo. Liver Int 2009; 29: 277-283 [PMID: 18397228 DOI: 10.1111/j.1478-3231.2008.01748.x]
87. Chen YB, Li SD, He YP, Shi XJ, Chen Y, Gong JP. Immunosuppressive effect of IDO on T cells in patients with chronic hepatitis B∗. Hepatol Res 2009; 39: 463-468 [PMID: 19207575 DOI: 10.1111/j.1872-034X.2008.00476.x]
88. Mao R, Zhang J, Jiang D, Cai D, Levy JM, Cuconati A, Block TM, Guo JT, Guo H. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol 2011; 85: 1048-1057 [PMID: 21084489 DOI: 10.1128/JVI.01998-10]
89. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 2008; 4: e1000007 [PMID: 18389079 DOI: 10.1371/journal.ppat.1000007]
90. Eldin P, Papon L, Oteiza A, Brocchi E, Lawson TG, Mechti N. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 2009; 90: 536-545 [PMID: 19218198 DOI: 10.1099/vir.0.006288-0]
91. Di Pietro A, Kajaste-Rudnitski A, Oteiza A, Nicora L, Towers GJ, Mechti N, Vicenzi E. TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol 2013; 87: 4523-4533 [PMID: 23408607 DOI: 10.1128/JVI.02548-12]
92. Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 2009; 50: 424-433 [PMID: 19585648 DOI: 10.1002/hep.23011]
93. Terenzi F, Hui DJ, Merrick WC, Sen GC. Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. J Biol Chem 2006; 281: 34064-34071 [PMID: 16973618 DOI: 10.1074/jbc.M605771200]
94. Guo J, Hui DJ, Merrick WC, Sen GC. A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J 2000; 19: 6891-6899 [PMID: 11118224 DOI: 10.1093/emboj/19.24.6891]
95. Pichlmair A, Lassnig C, Eberle CA, Górna MW, Baumann CL, Burkard TR, Bürckstümmer T, Stefanovic A, Krieger S, Bennett KL, Rülicke T, Weber F, Colinge J, Müller M, Superti-Furga G. IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat Immunol 2011; 12: 624-630 [PMID: 21642987 DOI: 10.1038/ni.2048]
96. Pei R, Qin B, Zhang X, Zhu W, Kemper T, Ma Z, Trippler M, Schlaak J, Chen X, Lu M. Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J Innate Immun 2014; 6: 182-191 [PMID: 23867918 DOI: 10.1159/000353220]
97. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov 2012; 7: 597-611 [PMID: 22607384 DOI: 10.1517/17460441.2012.689281]
98. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272 [PMID: 15890966 DOI: 10.1128/JVI.79.11.7269-7272.2005]
99. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, Halcomb RL, Tumas DB. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013; 144: 1508-1517, 1517.e1-10 [PMID: 23415804]
100. Xia C, Lu M, Zhang Z, Meng Z, Zhang Z, Shi C. TLRs antiviral effect on hepatitis B virus in HepG2 cells. J Appl Microbiol 2008; 105: 1720-1727 [PMID: 19149768 DOI: 10.1111/j.1365-2672.2008.03896.x]
101. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 2009; 83: 847-858 [PMID: 18971270 DOI: 10.1128/JVI.02008-08]
102. Thompson AJ, Colledge D, Rodgers S, Wilson R, Revill P, Desmond P, Mansell A, Visvanathan K, Locarnini S. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther 2009; 14: 797-808 [PMID: 19812442 DOI: 10.3851/1294]
103. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 2012; 57: 522-528 [PMID: 22617154 DOI: 10.1016/j.jhep.2012.05.004]
104. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46: 1769-1778 [PMID: 17929296 DOI: 10.1002/hep.21897]
105. Chang J, Block TM, Guo JT. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 2012; 96: 405-413 [PMID: 23072881 DOI: 10.1016/j.antiviral.2012.10.001]
106. Liu J, Jiang M, Ma Z, Dietze KK, Zelinskyy G, Yang D, Dittmer U, Schlaak JF, Roggendorf M, Lu M. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro. J Immunol 2013; 191: 6178-6190 [PMID: 24227786 DOI: 10.4049/jimmunol.1301262]
107. Li Y, Shi X. MicroRNAs in the regulation of TLR and RIG-I pathways. Cell Mol Immunol 2013; 10: 65-71 [PMID: 23262976]
108. Quinn SR, O'Neill LA. A trio of microRNAs that control Toll-like receptor signalling. Int Immunol 2011; 23: 421-425 [PMID: 21652514 DOI: 10.1093/intimm/dxr034]
109. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011; 53: 1476-1485 [PMID: 21520166]
110. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010; 88: 169-175 [PMID: 20728471 DOI: 10.1016/j.antiviral.2010.08.008]
111. Zhang X, Hou J, Lu M. Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet 2013; 4 : 202 [PMID: 24133502 DOI: 10.3389/fgene.2013.00202]
112. Xie Q, Shen HC, Jia NN, Wang H, Lin LY, An BY, Gui HL, Guo SM, Cai W, Yu H, Guo Q, Bao S. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect 2009; 11 : 515-523 [PMID: 19289178 DOI: 10.1016/j.micinf.2009.02.008]
113. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trépo C, Hasan U, Chemin I. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 2011; 6: e26315 [PMID: 22046272 DOI: 10.1371/journal.pone.0026315]
114. Xu N, Yao HP, Lv GC, Chen Z. Downregulation of TLR7/9 leads to deficient production of IFN-α from plasmacytoid dendritic cells in chronic hepatitis B. Inflamm Res 2012; 61: 997-1004 [PMID: 22684144 DOI: 10.1007/s00011-012-0493-z]
115. Huang YW, Lin SC, Wei SC, Hu JT, Chang HY, Huang SH, Chen DS, Chen PJ, Hsu PN, Yang SS, Kao JH. Reduced Toll-like receptor 3 expression in chronic hepatitis B patients and its restoration by interferon therapy. Antivir Ther 2013; 18: 877-884 [PMID: 23744559 DOI: 10.3851/IMP2630]
116. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z, Shen F, Yuan Z. Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol 2008; 128 : 400-408 [PMID: 18565796 DOI: 10.1016/j.clim.2008.04.006]
117. Wang H, Ryu WS. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog 2010; 6: e1000986 [PMID: 20657822 DOI: 10.1371/journal.ppat.1000986]
118. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009; 49: 1132-1140 [PMID: 19140219 DOI: 10.1002/hep.22751]
119. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z. HBsAg inhibits TLR9-mediated activation and IFN-alpha production in plasmacytoid dendritic cells. Mol Immunol 2009; 46: 2640-2646 [PMID: 19501403 DOI: 10.1016/j.molimm.2009.04.031]
120. Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, Yuan Z. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013; 190: 5142-5151 [PMID: 23585678 DOI: 10.4049/jimmunol.1201625]
121. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann JH, Pollok JM, Lohse AW, Petersen J, Dandri M. Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 2011; 140: 2074-2083, 2083.e1-2 [PMID: 21376046 DOI: 10.1053/j.gastro.2011.02.057]
122. Chen J, Wu M, Zhang X, Zhang W, Zhang Z, Chen L, He J, Zheng Y, Chen C, Wang F, Hu Y, Zhou X, Wang C, Xu Y, Lu M, Yuan Z. Hepatitis B virus polymerase impairs interferon-α-induced STA T activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 2013; 57: 470-482 [PMID: 22996189 DOI: 10.1002/hep.26064]
123. Wang Y, Wei L, Jiang D, Cong X, Fei R, Xiao J, Wang Y. In vitro resistance to interferon of hepatitis B virus with precore mutation. World J Gastroenterol 2005; 11: 649-655 [PMID: 15655815]
124. Wang Y, Wei L, Jiang D, Cong X, Fei R, Chen H, Xiao J, Wang Y. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation. Antiviral Res 2007; 75: 139-145 [PMID: 17397939 DOI: 10.1016/j.antiviral.2007.02.001]
125. Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2012; 56: 67-75 [PMID: 22307831 DOI: 10.1002/hep.25636]
126. Sonneveld MJ, Rijckborst V, Zwang L, Zeuzem S, Jenny Heathcote E, Simon K, Zoutendijk R, Akarca US, Pas SD, Hansen BE, Janssen HL. Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. Antiviral Res 2013; 97 : 312-317 [PMID: 23274785 DOI: 10.1016/j.antiviral.2012.12.023]
127. Lu JJ, Chen EQ, Yang JH, Zhou TY, Liu L, Tang H. A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients. Virol J 2012; 9: 10 [PMID: 22233973 DOI: 10.1186/1743-422X-9-10]
128. Radecke K, Protzer U, Trippler M, Meyer Zum Büschenfelde KH, Gerken G. Selection of hepatitis B virus variants with aminoacid substitutions inside the core antigen during interferon-alpha therapy. J Med Virol 2000; 62: 479-486 [PMID: 11074477]